Applicants : KING and ZHENG Atty. Dkt. No. : 873-Z-US U.S. Serial No.: 10/738,423 Art Unit : 1633

U.S. Serial No.: 10/738,423 Art Unit : 1633

Filed : 12/16/2003 Date of office action : 9/28/2007

Examiner : Qian Janice Li Date of response : 10/22/2007

Page: 3

Amendment(s) to the claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1.-112. (Canceled)

(Amended) A method of inhibiting the growth of, or reducing the volume of a solid tumor cancer, comprising administering to a subject having a solid tumor cancer an effective amount of cytoxan or cisplatin and an effective a pharmaceutical composition comprising amount of pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria Salmonella, wherein the Salmonella comprises an msbB mutant.

114. (Cancelled).

- 115. (Previously presented) The method of claim 113 wherein, the solid tumor or cancer is either a lung cancer or colon cancer.
- 116. (Previously presented) The method of claim 113 wherein the subject is a mammal.
- 117. (Previously presented) The method of claim 113 wherein the subject is a human.
- 118. (Withdrawn) The method of claim 113, comprising administering an effective amount of cytoxan.
- 119. (Previously presented) The method of claim 113, comprising administering an effective amount of cisplatin.

Applicants : KING and ZHENG Atty. Dkt. No. : 873-Z-US U.S. Serial No.: 10/738,423 Art Unit : 1633

Filed : 12/16/2003 Date of office action : 9/28/2007 Examiner : Qian Janice Li Date of response : 10/22/2007

Page : 4

120. (New) The method of claim 113, wherein the administering of the attenuated tumor-targeted Salmonella msbB and the administering of the cytoxan or cisplatin are not performed concomitantly.

- 121. (New) The method of claim 115, wherein the solid tumor cancer is a lung cancer.
- 122. (New) The method of claim 115, wherein the solid tumor cancer is a lung cancer.
- 123. (New) A method of inhibiting the growth of, or reducing the volume of a solid tumor cancer, comprising administering to a subject having a solid tumor cancer an effective amount of,
 - (a) a pharmaceutical composition consisting essentially of an anti-cancer compound and one or more pharmaceutically acceptable carriers, and
 - (b) an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted Salmonella, wherein the Salmonella comprises an msbB mutant.
- 124. (New) The method of claim 123 wherein the anti-cancer compound is cisplatin.
- 125. (New) The method of claim 123 wherein the anti-cancer compound is cytoxan.